Index -
P/E -
EPS (ttm) -
Insider Own 53.70%
Shs Outstand 31.85M
Perf Week -4.35%
Market Cap 720.45M
Forward P/E -
EPS next Y -
Insider Trans 98.80%
Shs Float 14.75M
Perf Month -
Income -
PEG -
EPS next Q -
Inst Own -
Short Float -
Perf Quarter -
Sales -
P/S -
EPS this Y -
Inst Trans -
Short Ratio -
Perf Half Y -
Book/sh -3.07
P/B -
EPS next Y -
ROA -
Short Interest -
Perf Year -
Cash/sh 1.74
P/C 13.04
EPS next 5Y -
ROE -
52W Range 20.29 - 26.08
Perf YTD -4.35%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -
52W High -13.27%
Beta -
Dividend TTM -
Quick Ratio 7.17
Sales past 5Y 0.00%
Gross Margin -
52W Low 11.51%
ATR (14) 2.78
Dividend Ex-Date -
Current Ratio 7.17
EPS Y/Y TTM -
Oper. Margin -
RSI (14) -
Volatility - -
Employees -
Debt/Eq 0.01
Sales Y/Y TTM -
Profit Margin -
Recom -
Target Price -
Option/Short No / Yes
LT Debt/Eq 0.00
EPS Q/Q -
Payout -
Rel Volume 0.80
Prev Close 21.23
Sales Surprise -
EPS Surprise -
Sales Q/Q -
Earnings -
Avg Volume 469.70K
Price 22.62
SMA20 3.73%
SMA50 3.73%
SMA200 3.73%
Trades
Volume 329,750
Change 6.55%
Sep-18-24 03:19AM
Sep-16-24 04:05PM
Sep-12-24 07:11PM
MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of peptide therapies for the treatment of endocrine and metabolic disorders. Its product candidates and programs include MBX 2109, MBX 1416, and obesity portfolio. The company was founded by Peter Kent Hawryluk and Richard D. DiMarchi in August 2018 and is headquartered in Carmel, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Mathers Edward T Director Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:28 PM BASKETT FOREST 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:26 PM Behbahani Ali 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:24 PM Chang Carmen 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:23 PM Florence Anthony A. Jr. 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:21 PM Makhzoumi Mohamad 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:20 PM Walker Paul Edward 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:18 PM Yang Rick 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:17 PM SANDELL SCOTT D 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:14 PM ORBIMED ADVISORS LLC Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:13 PM New Enterprise Associates 17, 10% Owner Sep 16 '24 Buy 16.00 500,000 8,000,000 3,614,486 Sep 17 08:12 PM Frazier Life Sciences X, L.P. 10% Owner Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:11 PM Heron Patrick J Director Sep 16 '24 Buy 16.00 625,000 10,000,000 4,552,774 Sep 17 08:09 PM Aynechi Tiba Director Sep 16 '24 Buy 16.00 750,000 12,000,000 2,136,335 Sep 17 08:05 PM GORDON CARL L Director Sep 16 '24 Buy 16.00 750,000 12,000,000 3,158,428 Sep 17 08:05 PM
Index RUT
P/E -
EPS (ttm) -25.49
Insider Own 36.37%
Shs Outstand 8.02M
Perf Week -14.68%
Market Cap 328.75M
Forward P/E -
EPS next Y -9.79
Insider Trans 5.57%
Shs Float 5.92M
Perf Month -23.19%
Income -92.22M
PEG -
EPS next Q -2.55
Inst Own 62.88%
Short Float 4.86%
Perf Quarter -0.08%
Sales 0.00M
P/S -
EPS this Y 82.24%
Inst Trans -28.19%
Short Ratio 3.31
Perf Half Y -45.62%
Book/sh 21.34
P/B 1.66
EPS next Y -3.86%
ROA -56.06%
Short Interest 0.29M
Perf Year 257.97%
Cash/sh 17.12
P/C 2.07
EPS next 5Y -
ROE -75.75%
52W Range 4.57 - 97.91
Perf YTD -26.25%
Dividend Est. -
P/FCF -
EPS past 5Y -11.67%
ROI -39.06%
52W High -63.90%
Beta 3.85
Dividend TTM -
Quick Ratio 13.28
Sales past 5Y -26.84%
Gross Margin -
52W Low 672.68%
ATR (14) 4.27
Dividend Ex-Date -
Current Ratio 13.28
EPS Y/Y TTM 73.20%
Oper. Margin 0.00%
RSI (14) 37.16
Volatility 9.81% 10.12%
Employees 101
Debt/Eq 0.19
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 123.75
Option/Short No / Yes
LT Debt/Eq 0.19
EPS Q/Q 83.89%
Payout -
Rel Volume 0.86
Prev Close 38.50
Sales Surprise -
EPS Surprise -0.06%
Sales Q/Q -
Earnings Aug 13 AMC
Avg Volume 86.90K
Price 35.35
SMA20 -17.79%
SMA50 -19.10%
SMA200 -31.00%
Trades
Volume 65,600
Change -8.18%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-14-24 Initiated
William Blair
Outperform
$180
Mar-28-24 Reiterated
H.C. Wainwright
Buy
$100 → $115
Feb-27-24 Initiated
BMO Capital Markets
Outperform
$120
Dec-04-23 Initiated
H.C. Wainwright
Buy
$100
Nov-29-23 Initiated
RBC Capital Mkts
Outperform
$70
Nov-10-23 Initiated
Piper Sandler
Overweight
$180
Feb-15-23 Downgrade
Chardan Capital Markets
Buy → Neutral
Feb-13-23 Downgrade
Cowen
Outperform → Market Perform
Sep-22-21 Downgrade
Goldman
Buy → Neutral
$12 → $9
Jan-27-21 Upgrade
JP Morgan
Neutral → Overweight
$56
Dec-22-20 Initiated
B. Riley Securities
Buy
$79
Jul-14-20 Initiated
Oppenheimer
Outperform
$36
May-18-20 Downgrade
JP Morgan
Overweight → Neutral
$27
Oct-28-19 Initiated
JP Morgan
Overweight
$25
Oct-28-19 Initiated
Goldman
Buy
$30
Oct-28-19 Initiated
Cowen
Outperform
Show Previous Ratings
Sep-16-24 08:00AM
Sep-10-24 08:00AM
Aug-28-24 08:00AM
Aug-27-24 08:00AM
Aug-13-24 04:01PM
08:00AM
Loading…
Jul-01-24 08:00AM
Jun-25-24 12:53PM
May-30-24 04:01PM
May-20-24 02:30PM
May-14-24 10:55PM
04:01PM
Apr-18-24 08:30AM
Apr-01-24 04:01PM
Mar-26-24 04:01PM
Feb-27-24 09:55AM
08:00AM
Loading…
08:00AM
Feb-09-24 09:55AM
Jan-18-24 08:00AM
Jan-04-24 08:00AM
Dec-07-23 08:00AM
Nov-28-23 08:00AM
Nov-03-23 03:31PM
12:19PM
Aug-10-23 04:01PM
Jul-17-23 11:59AM
Jul-14-23 11:22AM
06:30AM
May-12-23 04:01PM
Mar-10-23 07:30AM
Feb-27-23 07:30AM
01:55PM
Loading…
Feb-13-23 01:55PM
(American City Business Journals) -80.54%
11:17AM
08:05AM
Dec-19-22 07:30AM
Dec-15-22 07:30AM
Nov-17-22 07:30AM
Nov-08-22 04:05PM
Oct-12-22 07:30AM
Aug-30-22 07:30AM
Aug-09-22 04:05PM
(Business Wire) -11.11%
+9.00%
Jun-24-22 09:03AM
May-25-22 12:00PM
May-18-22 07:30AM
May-04-22 04:30PM
Apr-22-22 07:30AM
Apr-08-22 05:00PM
Mar-15-22 07:30AM
Mar-10-22 06:35PM
Feb-28-22 07:30AM
Jan-14-22 05:43AM
Jan-04-22 07:30AM
Dec-28-21 02:38AM
Dec-09-21 01:18PM
07:30AM
Nov-30-21 05:53AM
Nov-15-21 12:25PM
07:30AM
Nov-09-21 07:30AM
Nov-08-21 03:00PM
Oct-27-21 07:30AM
Oct-21-21 07:30AM
Oct-01-21 08:23AM
Sep-22-21 11:18AM
07:30AM
Sep-08-21 07:30AM
Aug-30-21 05:10PM
Aug-12-21 04:06PM
08:45AM
07:30AM
Aug-04-21 03:00PM
Aug-02-21 03:05PM
02:30PM
12:30PM
12:30PM
11:00AM
10:00AM
09:16AM
09:09AM
05:50AM
03:27AM
Aug-01-21 10:38AM
06:36AM
Jul-30-21 08:49PM
07:19PM
07:10PM
05:15PM
02:57PM
01:30PM
12:40PM
11:30AM
11:30AM
11:00AM
10:00AM
10:00AM
09:30AM
09:00AM
05:18AM
Jul-29-21 08:47PM
05:29PM
04:02PM
Korro Bio, Inc. is an RNA editing company, which engages in the discovery and development of genetic medicines. The company was founded by Nessan Bermingham, Jean-Francois Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Colletti Steve Former Officer Aug 30 '24 Proposed Sale 49.24 10,303 507,326 Aug 30 05:28 PM New Enterprise Associates 17, 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM BASKETT FOREST 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Florence Anthony A. Jr. 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Walker Paul Edward 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Chang Carmen 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Mathers Edward T 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Yang Rick 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Makhzoumi Mohamad 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM SANDELL SCOTT D 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 1,090,793 Apr 24 05:00 PM Atlas Venture Opportunity Fund 10% Owner Apr 22 '24 Buy 56.00 17,857 999,992 195,074 Apr 23 05:23 PM Lucchino David L. Director Nov 22 '23 Sale 37.69 1,156 43,573 22,150 Nov 27 08:48 PM Lucchino David L. Director Nov 10 '23 Sale 41.97 968 40,632 23,306 Nov 22 04:05 PM
Index RUT
P/E -
EPS (ttm) -0.42
Insider Own 44.31%
Shs Outstand 138.14M
Perf Week 9.79%
Market Cap 759.00M
Forward P/E -
EPS next Y -0.43
Insider Trans 0.00%
Shs Float 91.67M
Perf Month 2.93%
Income -75.29M
PEG -
EPS next Q -0.11
Inst Own 51.05%
Short Float 10.27%
Perf Quarter 18.85%
Sales 0.00M
P/S -
EPS this Y -35.06%
Inst Trans 2.44%
Short Ratio 5.34
Perf Half Y -5.70%
Book/sh 0.74
P/B 6.26
EPS next Y 3.85%
ROA -58.02%
Short Interest 9.41M
Perf Year 22.31%
Cash/sh 0.74
P/C 6.25
EPS next 5Y -
ROE -79.48%
52W Range 3.12 - 5.70
Perf YTD -1.89%
Dividend Est. -
P/FCF -
EPS past 5Y 29.09%
ROI -58.72%
52W High -19.10%
Beta 0.96
Dividend TTM -
Quick Ratio 11.29
Sales past 5Y -20.00%
Gross Margin -
52W Low 48.03%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 11.29
EPS Y/Y TTM -51.68%
Oper. Margin 0.00%
RSI (14) 59.03
Volatility 5.14% 4.97%
Employees 37
Debt/Eq 0.26
Sales Y/Y TTM -
Profit Margin -
Recom 1.00
Target Price 10.79
Option/Short Yes / Yes
LT Debt/Eq 0.26
EPS Q/Q -62.62%
Payout -
Rel Volume 0.58
Prev Close 4.64
Sales Surprise -
EPS Surprise -15.05%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 1.76M
Price 4.61
SMA20 6.05%
SMA50 4.64%
SMA200 1.20%
Trades
Volume 890,222
Change -0.62%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Initiated
JMP Securities
Mkt Outperform
$8
Nov-07-23 Initiated
Guggenheim
Buy
$7
May-16-23 Upgrade
Jefferies
Hold → Buy
$2 → $4
Mar-31-23 Downgrade
Jefferies
Buy → Hold
$2
Mar-16-21 Initiated
Piper Sandler
Overweight
$7
Mar-15-21 Initiated
Oppenheimer
Outperform
$4
Jun-13-19 Reiterated
H.C. Wainwright
Buy
$22 → $6
Jun-13-19 Downgrade
Ladenburg Thalmann
Buy → Neutral
$21 → $3
Jun-13-19 Downgrade
JMP Securities
Mkt Outperform → Mkt Perform
Aug-13-18 Resumed
ROTH Capital
Neutral
$12
Jan-03-18 Initiated
Ladenburg Thalmann
Buy
$35
Sep-27-17 Resumed
ROTH Capital
Buy
$40
Sep-22-17 Initiated
Jefferies
Buy
$20
Sep-11-17 Initiated
JMP Securities
Mkt Outperform
$20
Show Previous Ratings
Sep-08-24 06:45AM
Sep-06-24 04:05PM
Sep-03-24 04:05PM
Sep-01-24 10:26PM
Aug-29-24 08:41PM
04:05PM
Loading…
Aug-16-24 04:05PM
Aug-15-24 08:05AM
Aug-12-24 04:05PM
Jun-29-24 08:35PM
06:30PM
Jun-28-24 08:50AM
Jun-26-24 07:41AM
06:30AM
Jun-25-24 08:05PM
Jun-19-24 09:00AM
06:00AM
Loading…
Jun-11-24 06:00AM
May-29-24 08:05AM
May-21-24 08:20AM
May-19-24 12:15PM
May-16-24 04:05PM
May-09-24 10:55PM
04:05PM
May-07-24 04:05PM
(Business Wire) +6.26%
-5.13%
Apr-08-24 08:05AM
Mar-22-24 04:05PM
Mar-07-24 10:54PM
04:05PM
Mar-06-24 04:05PM
Feb-02-24 08:05AM
Jan-31-24 08:05AM
03:01PM
Loading…
Dec-30-23 03:01PM
Dec-21-23 08:05AM
Dec-20-23 08:05AM
Dec-15-23 04:05PM
Nov-21-23 08:05AM
Nov-09-23 04:05PM
Nov-08-23 04:05PM
Oct-06-23 04:05PM
Sep-27-23 07:29PM
Sep-17-23 10:54AM
Sep-12-23 09:12AM
Sep-05-23 04:05PM
Aug-10-23 04:05PM
Aug-04-23 04:05PM
Jul-13-23 07:00AM
Jun-26-23 04:05PM
08:05AM
Jun-02-23 08:05AM
May-28-23 08:26AM
May-16-23 12:32PM
May-15-23 08:05AM
May-05-23 04:05PM
Apr-03-23 07:33AM
Mar-31-23 04:05PM
Mar-30-23 04:05PM
Mar-20-23 06:35AM
Mar-17-23 06:47AM
Mar-16-23 06:51AM
Mar-15-23 06:44AM
Mar-13-23 06:32AM
Mar-10-23 07:04AM
Mar-09-23 06:33AM
Mar-08-23 06:30AM
Mar-07-23 06:34AM
Mar-06-23 04:05PM
07:22AM
Mar-03-23 06:38AM
Mar-02-23 06:44AM
Mar-01-23 06:01AM
Feb-28-23 04:05PM
06:43AM
Feb-27-23 06:50AM
Feb-23-23 07:21AM
Feb-22-23 06:56AM
Feb-21-23 07:35AM
Feb-17-23 06:27AM
Feb-16-23 07:28AM
Feb-15-23 07:01AM
06:24AM
Feb-14-23 08:05AM
06:23AM
Feb-13-23 07:30AM
Feb-10-23 06:42AM
Feb-09-23 06:51AM
Feb-08-23 06:45AM
Feb-07-23 06:46AM
Feb-06-23 06:56AM
Feb-03-23 06:32AM
Feb-02-23 06:43AM
Feb-01-23 06:14AM
Jan-31-23 06:50AM
Jan-30-23 06:42AM
Jan-27-23 03:47PM
07:00AM
Jan-26-23 06:44AM
Jan-25-23 06:39AM
Jan-24-23 06:48AM
Jan-23-23 06:58AM
Jan-20-23 08:05AM
06:55AM
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pauls Matthew CHIEF EXECUTIVE OFFICER Dec 28 '23 Sale 4.71 84,000 395,900 1,302,674 Dec 29 04:35 PM Lowrance David L CHIEF FINANCIAL OFFICER Dec 28 '23 Sale 4.71 10,000 47,131 342,355 Dec 29 04:34 PM Elam Nevan C Director Dec 28 '23 Option Exercise 1.30 53,758 69,722 116,343 Dec 29 04:33 PM Elam Nevan C Director Dec 28 '23 Sale 4.71 93,843 442,291 22,500 Dec 29 04:33 PM Hawkins Richard J Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 12,741 Dec 12 06:09 PM Elam Nevan C Director Dec 11 '23 Option Exercise 0.82 10,841 8,890 40,085 Dec 12 06:08 PM
Index RUT
P/E -
EPS (ttm) -1.08
Insider Own 24.92%
Shs Outstand 52.28M
Perf Week 11.45%
Market Cap 4.61B
Forward P/E -
EPS next Y -2.28
Insider Trans -5.58%
Shs Float 40.36M
Perf Month 28.59%
Income -53.89M
PEG -
EPS next Q -0.33
Inst Own 81.58%
Short Float 12.54%
Perf Quarter 52.69%
Sales 144.75M
P/S 31.83
EPS this Y 3.98%
Inst Trans 15.14%
Short Ratio 11.14
Perf Half Y 18.95%
Book/sh 9.08
P/B 9.43
EPS next Y -61.66%
ROA -7.94%
Short Interest 5.06M
Perf Year 148.31%
Cash/sh 9.61
P/C 8.91
EPS next 5Y -
ROE -13.80%
52W Range 30.88 - 86.11
Perf YTD 54.40%
Dividend Est. -
P/FCF -
EPS past 5Y -29.89%
ROI -10.07%
52W High -0.48%
Beta 0.24
Dividend TTM -
Quick Ratio 6.01
Sales past 5Y 0.00%
Gross Margin 97.77%
52W Low 177.50%
ATR (14) 3.47
Dividend Ex-Date -
Current Ratio 6.01
EPS Y/Y TTM 73.62%
Oper. Margin -55.73%
RSI (14) 81.16
Volatility 4.21% 4.65%
Employees 130
Debt/Eq 0.15
Sales Y/Y TTM 349.32%
Profit Margin -37.23%
Recom 1.12
Target Price 81.64
Option/Short Yes / Yes
LT Debt/Eq 0.10
EPS Q/Q -2.50%
Payout -
Rel Volume 1.42
Prev Close 85.43
Sales Surprise 24.27%
EPS Surprise 1.72%
Sales Q/Q 91.47%
Earnings Aug 08 AMC
Avg Volume 454.23K
Price 85.69
SMA20 17.92%
SMA50 30.48%
SMA200 43.03%
Trades
Volume 561,496
Change 0.31%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-03-24 Initiated
Cantor Fitzgerald
Overweight
May-31-24 Initiated
Piper Sandler
Overweight
$70
Mar-07-24 Initiated
Morgan Stanley
Overweight
$81
Jan-04-24 Reiterated
Needham
Buy
$65 → $71
Dec-19-23 Initiated
Scotiabank
Sector Outperform
$66
Oct-30-23 Initiated
TD Cowen
Outperform
Oct-17-23 Initiated
UBS
Buy
$52
May-18-23 Initiated
Truist
Buy
$60
Apr-14-23 Initiated
Robert W. Baird
Outperform
$39
Mar-14-23 Initiated
Stifel
Buy
$43
Feb-13-23 Initiated
H.C. Wainwright
Buy
$42
Dec-13-22 Resumed
BofA Securities
Buy
$29 → $37
Oct-31-22 Initiated
Guggenheim
Buy
$36
Oct-27-22 Initiated
Needham
Buy
$31
Jul-20-22 Initiated
Canaccord Genuity
Buy
$32
Mar-01-22 Initiated
SVB Leerink
Outperform
$47
Mar-01-22 Initiated
BofA Securities
Buy
$24
Show Previous Ratings
Aug-08-24 05:25PM
04:00PM
Aug-02-24 06:53AM
Jul-04-24 02:13PM
Jun-29-24 03:08AM
04:42PM
Loading…
Jun-21-24 04:42PM
(Investor's Business Daily)
May-27-24 12:32PM
May-25-24 03:11AM
May-17-24 08:06AM
May-15-24 07:21AM
May-14-24 08:00AM
May-10-24 01:13PM
04:21AM
May-09-24 10:57PM
05:10PM
04:05PM
Loading…
04:05PM
04:05PM
04:00PM
06:49AM
May-07-24 04:00PM
May-03-24 05:57PM
Apr-23-24 11:26AM
Apr-04-24 04:00PM
08:40AM
Mar-29-24 02:57PM
Mar-28-24 08:13AM
Mar-27-24 01:50AM
Mar-20-24 04:00PM
Feb-29-24 04:00PM
Feb-28-24 07:30PM
04:00PM
Loading…
04:00PM
Feb-15-24 11:57AM
Jan-16-24 01:51PM
Dec-22-23 01:30AM
Dec-15-23 05:04PM
Dec-08-23 04:00PM
Nov-30-23 09:37PM
Nov-21-23 08:00AM
(Investor's Business Daily)
Nov-16-23 10:10AM
Nov-15-23 04:05PM
(Investor's Business Daily) +5.31%
09:47AM
09:22AM
07:16AM
06:00AM
06:00AM
Nov-13-23 04:47PM
04:00PM
Nov-09-23 11:14AM
08:30AM
Nov-02-23 09:40AM
09:00AM
Oct-26-23 04:00PM
Oct-23-23 02:50AM
Oct-17-23 09:40AM
Sep-29-23 12:43PM
Sep-04-23 09:55AM
Sep-01-23 09:18AM
Aug-17-23 09:55AM
Aug-16-23 01:21PM
Aug-14-23 04:00PM
Jul-31-23 07:13AM
Jul-25-23 02:37AM
Jun-26-23 12:48PM
Jun-22-23 11:04AM
Jun-21-23 10:38AM
Jun-20-23 04:05PM
(Investor's Business Daily) -7.18%
Jun-19-23 07:46PM
May-11-23 10:45AM
May-10-23 06:11AM
May-08-23 05:15PM
04:00PM
May-04-23 04:59AM
May-03-23 06:44AM
Apr-28-23 03:34PM
Apr-25-23 12:00PM
Apr-21-23 12:00PM
Apr-13-23 04:01PM
Apr-11-23 10:00AM
Apr-05-23 09:55AM
Apr-04-23 12:20PM
Apr-03-23 08:34AM
Mar-29-23 05:25PM
04:01PM
Mar-16-23 12:18PM
Feb-21-23 04:00PM
Feb-02-23 04:00PM
Jan-30-23 09:00AM
Jan-04-23 11:45AM
Dec-14-22 10:24AM
Dec-12-22 10:55AM
Dec-09-22 04:08PM
(Investor's Business Daily) +29.24%
09:54AM
09:42AM
08:46AM
08:17AM
08:17AM
08:15AM
Nov-30-22 11:08AM
Nov-14-22 04:00PM
01:13PM
Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Gaithersburg, MD.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Gilson Michelle CHIEF FINANCIAL OFFICER Sep 17 '24 Option Exercise 8.66 15,000 129,900 21,915 Sep 17 08:54 PM Gilson Michelle CHIEF FINANCIAL OFFICER Sep 17 '24 Sale 77.73 15,000 1,165,880 6,915 Sep 17 08:54 PM MICHELLE GILSON Officer Sep 17 '24 Proposed Sale 77.01 15,000 1,155,150 Sep 17 04:39 PM Patel Kavita Director Sep 10 '24 Option Exercise 6.66 1,500 9,990 1,500 Sep 12 06:27 PM Patel Kavita Director Sep 10 '24 Sale 74.41 1,500 111,615 0 Sep 12 06:27 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 05 '24 Option Exercise 15.00 3,421 51,315 12,699 Sep 06 05:48 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 05 '24 Sale 70.02 3,421 239,526 9,278 Sep 06 05:48 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 03 '24 Option Exercise 13.27 27,451 364,232 36,729 Sep 03 09:33 PM Heery Christopher CHIEF MEDICAL OFFICER Sep 03 '24 Sale 67.03 27,451 1,840,053 9,278 Sep 03 09:33 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 26 '24 Option Exercise 15.00 21,684 325,260 30,962 Aug 28 04:54 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 26 '24 Sale 71.12 21,684 1,542,274 9,278 Aug 28 04:54 PM CHRISTOPHER HEERY Officer Aug 26 '24 Proposed Sale 69.38 48,907 3,393,168 Aug 26 04:24 PM Patel Kavita Director Aug 20 '24 Option Exercise 6.66 1,500 9,990 1,500 Aug 22 04:01 PM Patel Kavita Director Aug 20 '24 Sale 65.88 1,500 98,820 0 Aug 22 04:01 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 16 '24 Option Exercise 6.28 5,450 34,226 14,728 Aug 19 04:39 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 16 '24 Sale 65.05 5,450 354,526 9,278 Aug 19 04:39 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 01 '24 Option Exercise 10.94 20,000 218,764 29,278 Aug 02 04:02 PM Heery Christopher CHIEF MEDICAL OFFICER Aug 01 '24 Sale 60.42 20,000 1,208,435 9,278 Aug 02 04:02 PM Patel Kavita Director Jul 30 '24 Option Exercise 6.66 1,500 9,990 1,500 Aug 01 05:24 PM Patel Kavita Director Jul 30 '24 Sale 61.97 1,500 92,949 0 Aug 01 05:24 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 16 '24 Option Exercise 6.28 10,901 68,458 20,179 Jul 18 06:44 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 16 '24 Sale 65.30 10,901 711,854 9,278 Jul 18 06:44 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 11 '24 Option Exercise 6.28 3,671 23,054 12,949 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 12 '24 Option Exercise 6.28 1,780 11,178 11,058 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 11 '24 Sale 60.01 3,671 220,302 9,278 Jul 12 06:39 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 12 '24 Sale 60.21 1,780 107,175 9,278 Jul 12 06:39 PM Patel Kavita Director Jul 09 '24 Option Exercise 6.66 1,500 9,990 1,500 Jul 11 04:04 PM Patel Kavita Director Jul 09 '24 Sale 56.63 1,500 84,947 0 Jul 11 04:04 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 01 '24 Option Exercise 11.93 20,000 238,646 29,278 Jul 03 04:05 PM Heery Christopher CHIEF MEDICAL OFFICER Jul 01 '24 Sale 55.39 20,000 1,107,763 9,278 Jul 03 04:05 PM Patel Kavita Director Jun 27 '24 Option Exercise 6.66 10,000 66,600 10,000 Jun 28 04:08 PM Patel Kavita Director Jun 27 '24 Sale 54.27 10,000 542,656 0 Jun 28 04:08 PM Gilson Michelle CHIEF FINANCIAL OFFICER Jun 26 '24 Sale 53.70 12,877 691,519 6,915 Jun 28 04:06 PM Heery Christopher CHIEF MEDICAL OFFICER Jun 12 '24 Option Exercise 11.53 20,000 230,554 29,278 Jun 14 04:31 PM Heery Christopher CHIEF MEDICAL OFFICER Jun 12 '24 Sale 55.13 20,000 1,102,668 9,278 Jun 14 04:31 PM Gilson Michelle CHIEF FINANCIAL OFFICER May 23 '24 Option Exercise 0.00 22,428 0 31,913 May 24 08:16 PM Gilson Michelle CHIEF FINANCIAL OFFICER May 24 '24 Sale 50.71 12,121 614,656 19,792 May 24 08:16 PM Heery Christopher CHIEF MEDICAL OFFICER May 01 '24 Option Exercise 6.28 18,168 114,095 27,106 May 03 05:50 PM Heery Christopher CHIEF MEDICAL OFFICER May 01 '24 Sale 51.33 18,168 932,557 8,938 May 03 05:50 PM Ware Olivia C Director Apr 16 '24 Option Exercise 7.61 9,402 71,549 9,402 Apr 18 04:01 PM Ware Olivia C Director Apr 16 '24 Sale 55.55 9,402 522,260 0 Apr 18 04:01 PM Elghandour Rami SEE REMARKS Apr 01 '24 Sale 67.09 23,086 1,548,887 69,253 Apr 03 04:44 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 22 '24 Option Exercise 6.28 20,000 125,600 50,303 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 26 '24 Option Exercise 6.28 5,450 34,226 14,388 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 22 '24 Sale 70.18 41,365 2,903,066 8,938 Mar 26 08:52 PM Heery Christopher CHIEF MEDICAL OFFICER Mar 26 '24 Sale 69.11 5,450 376,648 8,938 Mar 26 08:52 PM Carroll Jill Director Mar 21 '24 Sale 70.55 504,263 35,575,755 1,479,148 Mar 25 05:30 PM Gilson Michelle CHIEF FINANCIAL OFFICER Mar 18 '24 Sale 69.34 6,825 473,255 9,485 Mar 18 08:49 PM Ware Olivia C Director Mar 15 '24 Option Exercise 7.61 9,000 68,490 9,000 Mar 18 06:38 PM Ware Olivia C Director Mar 15 '24 Sale 70.40 9,000 633,582 0 Mar 18 06:38 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 09 '24 Sale 63.40 3,688 233,811 33,270 Feb 12 07:46 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 08 '24 Sale 62.29 3,456 215,290 36,958 Feb 12 07:46 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 12 '24 Sale 64.46 2,967 191,251 30,303 Feb 12 07:46 PM Elghandour Rami SEE REMARKS Feb 09 '24 Sale 63.40 13,886 880,340 103,508 Feb 12 07:43 PM Elghandour Rami SEE REMARKS Feb 08 '24 Sale 62.29 13,010 810,451 117,394 Feb 12 07:43 PM Elghandour Rami SEE REMARKS Feb 12 '24 Sale 64.46 11,169 719,948 92,339 Feb 12 07:43 PM Heery Christopher CHIEF MEDICAL OFFICER Feb 07 '24 Option Exercise 0.00 22,555 0 40,414 Feb 09 04:08 PM Elghandour Rami SEE REMARKS Feb 07 '24 Option Exercise 0.00 70,211 0 130,404 Feb 09 04:05 PM Heery Christopher Chief Medical Officer Jan 04 '24 Sale 55.27 7,598 419,926 17,859 Jan 08 04:06 PM Gilson Michelle Chief Financial Officer Jan 04 '24 Sale 55.27 8,514 470,551 16,310 Jan 08 04:04 PM Elghandour Rami See Remarks Jan 04 '24 Sale 55.27 29,073 1,606,804 60,193 Jan 08 04:02 PM Heery Christopher Chief Medical Officer Jan 03 '24 Option Exercise 0.00 16,519 0 25,457 Jan 04 07:32 PM Elghandour Rami See Remarks Jan 03 '24 Option Exercise 0.00 53,097 0 89,266 Jan 04 07:29 PM Heery Christopher Chief Medical Officer Dec 18 '23 Option Exercise 6.28 120,000 753,600 127,795 Dec 19 04:43 PM Heery Christopher Chief Medical Officer Dec 18 '23 Sale 50.17 120,000 6,020,281 7,795 Dec 19 04:43 PM Carroll Jill Director Dec 14 '23 Sale 49.13 504,263 24,774,441 1,983,411 Dec 18 04:47 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite